Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from
new analyses of previously completed clinical studies demonstrating that
patients with type 2 or type 1 diabetes achieved a greater proportion of
blood glucose measurements in the normal range when SYMLIN®
(pramlintide acetate) injection treatment was used along with insulin.
Two abstracts highlighting the analyses evaluated the proportion of
readings from self-monitored seven-point glucose profiles that fell
above, below or within glycemic targets based on guidelines set by the
American Diabetes Association (ADA) and American Association of Clinical
Endocrinologists (AACE). The data analyses are being presented at the 72nd
Scientific Sessions of the ADA in Philadelphia.
"These results showed that SYMLIN, when used with mealtime insulin,
helped patients maintain their blood sugar in the normal glucose range
on a daily basis," said David Maggs, M.D., vice president, medical
research and development, Amylin Pharmaceuticals. "These data provide a
'real-world' analysis into the management of daily glucose levels as
many patients, whether they have type 1 or type 2 diabetes, struggle to
maintain target blood glucose levels despite treatment with mealtime
insulin. Recognizing the important role it plays in helping patients
control blood sugar at mealtime, ADA/EASD included SYMLIN in their new
position statement on the treatment of hyperglycemia."
In April of this year, the ADA and the European Association for the
Study of Diabetes (EASD) published a new Position Statement on the
management of hyperglycemia in type 2 diabetes. The Position Statement
included key clinical considerations for the use of SYMLIN, reaffirming
its use in conjunction with mealtime insulin to decrease post-meal
Source: Amylin Pharmaceuticals, Inc.